Niki BioSolutions, Inc. Proceeds from Sale and Maturity of Marketable Securities
Niki BioSolutions, Inc. (NIKI) reported Proceeds from Sale and Maturity of Marketable Securities of $93.22 thousand for the 12-month period ending 2023-12-31, per its S-4/A filed 2026-05-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-05-11
| Period end | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|
| 2023-12-31 | $93.22K S-4/A · filed 2026-05-11 | |
| 2023-06-30 | $93.22K 6-K · filed 2024-12-20 | |
| 2021-12-31 | $20.12M 20-F · filed 2024-04-30 | |
| 2021-06-30 | $20.12M 6-K · filed 2022-09-30 | |
| 2020-12-31 | $952.20K 20-F · filed 2023-04-28 | |
| 2020-06-30 | $952.20K 6-K · filed 2021-09-15 | |
| 2019-12-31 | $999.11K 20-F/A · filed 2023-01-17 | |
| 2018-12-31 | $2.31K 20-F · filed 2021-04-19 |